Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy

Fanghua Chen¹,2, Junming Wang², Yingcheng Wu², Qiang Gao¹,2 and Shu Zhang¹,2*

¹ Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China, 2 Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China

Liver cancer is the fourth leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) accounts for about 85%-90% of all primary liver malignancies. However, only 20-30% of HCC patients are eligible for curative therapy mainly due to the lack of early-detection strategies, highlighting the significance of reliable and accurate biomarkers. The integration of multi-omics became an important tool for biomarker screening and unique alterations in tumor-associated genes, transcripts, proteins, post-translational modifications and metabolites have been observed. We here summarized the novel biomarkers for HCC diagnosis based on multi-omics technology as well as the clinical significance of these potential biomarkers in the early detection of HCC.

Keywords: hepatocellular carcinoma, multi-omics, biomarker, clinical diagnosis, early detection

INTRODUCTION

Liver cancer is one of the leading causes of cancer-related death worldwide (1). Hepatocellular carcinoma (HCC) accounts for > 80% of liver cancer and is usually developed from advanced chronic liver diseases (CLD) with hepatitis virus (mainly HBV and HCV) infection and alcoholic/nonalcoholic liver diseases (2–4). α-fetoprotein (AFP) (5) and Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) (6, 7), des-gamma-carboxy prothrombin (DCP) (6) and glypican-3 (GPC3) (8, 9) have been used for the clinical diagnosis of HCC. However, the complex pathology and individual heterogeneity of HCC pose great challenges for its early detection (10). Most HCC patients were found at late-stage and had a 5-year survival rate as low as 10.0% (11, 12). It was reported that the 5-year survival rate would be over 86.2% if the patients were given intervention at an early phase (13).

Multi-omics including genomics, epigenomics, transcriptomics, proteomics, glycomics/glycoproteomics and metabolomics can provide novel insights for HCC detection. For genomics and epigenomics, more evidence has shown that circulating tumor DNAs (ctDNAs) and their epigenetic changes could be used as reliable biomarkers (14–16). For transcriptomics, significant changes were observed in mRNAs and noncoding RNAs (miRNAs, IncRNAs, circRNAs) (17). For proteomics, potential protein biomarkers such as Golgi protein-73 (GP73) (18) and heat shock
protein 90α (Hsp90α) (19) were identified for HCC detection. For post-translational modifications (PTMs), glycosylation, phosphorylation, acetylation and ubiquitination can be considered for discovering novel biomarkers. Mass spectrometry (MS)-based glycomics/glycoproteomics technology enabled the researchers to characterize aberrant glycoforms and site-specific glycans (20). In addition, metabolomics has contributed to the diagnosis of HCC (21). This review focused on potential biomarkers for liver cancer diagnosis based on multi-omics strategies. Potential HCC biomarkers including genetic mutations, epigenetic changes, mRNAs, noncoding RNAs, proteins, PTMs and metabolites have been summarized in Table 1.

### 1 GENETIC ALTERATION OF HCC

Circulating cell-free DNAs (cfDNAs) are DNA fragments released into the peripheral circulation after the degradation of cell components. The increased proliferation and metabolism of tumor cells would release abundant cfDNAs, which could be used as biomarkers (92–96). The conventional genetic changes of HCC, including point mutations, microsatellite changes and chromosomal rearrangements are reflected in cfDNAs. It was reported that about 50 somatic alterations had been detected and then they could cause changes of their corresponding proteins in HCC (97, 98). Among 48 patients, 56.3% of patients had at least one mutation of the four sites in the following three genes (c.747 for TP53, c.121, c.133 for CTNNB1 and c.1-124 for TRET), which could be further found in 22.2% of HCC patients’ tissues (22, 23). Moreover, the R249S mutation in TP53 was proved to have a potential diagnostic value in the test of 895 HCC patients (24). Other mutation sites of TP53, such as 157 (25), 175 (26), 245 (27), 248 (28) and 273 (29) have been considered for HCC detection. In addition, amino acid changes, such as S37 and S33, could be used as available monitoring indicators for HCC (35–37). The combination of cfDNA mutations and protein changes can increase the diagnosis accuracy of HCC. For example, HCC diagnosis using TP53, TERT, CTNNB1, AFP and DCP has achieved satisfactory results (38).

Epigenetic alterations of cfDNAs were associated with HCC. Methylation changes of cfDNAs often occur in the early stage of tumorigenesis, particularly those alterations in the CpG islands of anti-oncogenes, which may play critical roles in the initiation and progression of HCC (99). The 5-hydroxymethylcytosines (5hmC) are abundantly expressed epigenetic markers (100). A 32-gene diagnostic model was developed using the 5hmC-Seq technique, which accurately distinguished early-stage HCC from non-HCC (32). Accumulating studies have also reported the aberrant methylation of glutathione S-transferase pi-1 (GSTP1) promoter region and cyclin-dependent kinase inhibitor p15 and p16 in HCC patients (101–103). Moreover, the combination of several hot methylated genes was utilized for HCC diagnosis. For example, p16, p15 and ras association domain family 1A (RASSF1A) were assessed in 50 HCC patients and they provided an overall predictive accuracy of 89% with a sensitivity of 84% and a specificity of 94% (56). A panel of four genes (APC, GSTP1, RASSF1A and SFRP1) could make a distinction between HCC and normal controls with a sensitivity of 92.7% and a specificity of 81.9% (104). A predictive model that consisted of three abnormally methylated genes (APC, COX2 and RASSF1A) and one miRNA (miR-203) could be considered to diagnose HCC (40, 105).

### 2 TRANSCRIPTOMICS OF HCC

Analysis of differential gene expression was important for HCC detection. Three genes (FCN3, CLEC1B and PRC1) were explored to be HCC biomarkers based on large-scale transcriptome datasets (30). It was found that YWHAZ, ENAH, HMGN4 and CAPIRNI changed significantly in HCC (48). Transcriptomics can be integrated into other omics for biomarkers screening. A transcriptome-proteome assay was performed to track the possible biomarkers from HCC-derived gene expression to its protein product released into serum, and a candidate biomarker, Hsp90α, was identified (106).

Long noncoding RNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs) play important roles in the epigenetic regulation of gene expression (107–109). Especially, lncRNAs can affect the expression and stability of miRNAs and messenger RNAs (mRNAs) (110–112). It was reported that lncRNAs HULC and CYTOR were used for joint diagnosis of HCC (39). Moreover, a diagnostic panel including lncRNAs CYTOR, UCA1 and AFP had satisfactory sensitivity and specificity (31).

miRNAs are small noncoding RNAs composed of 20-24 nucleotides. Elevated miR-21 levels in HCC patients have been widely reported (32). The high expression of miR-224 had a good diagnostic value with an AUC of 0.888-0.899 for patients with early HCC (45). It was reported that the overexpression of eight miRNAs (miR-20a-5p, miR-25-3p, miR-30a-5p, miR-92a-3p, miR-132-3p, miR-185-5p, miR-320a and miR-324-3p) had diagnostic significance in HBV positive HCC patients. Besides, the four miRNAs (miR-20a-5p, miR-320a, miR-324-3p and miR-375) panel could contribute to the early screening of HCC (49). Zhou et al. found plasma miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801 were potential circulating biomarkers for HCC (75). This seven-miRNA panel showed high accuracy in the diagnosis of HCC, even in patients with early stages. The miRNA panel enabled a more detailed distinction among HCC, healthy, chronic HBV and cirrhosis. It has been evaluated by multi-center clinical detection and authorized by National Medical Products Administration in China.

The changes in circRNA expression were also observed in HCC patients (113). For example, cSMARCA5 (41, 42), circ-ZEB1.33 (33) and circ_0001445 (46) levels were notably decreased in HCC patients. Two circRNAs (circ_000244 and circ_104075) were upregulated in HCC tissues and sera. The circ_104075 exhibited better sensitivity and specificity than some traditional HCC biomarkers (53). The circ_000244 showed better diagnostic performance than AFP (50).
TABLE 1 | Potential biomarkers for HCC based on multi-omics strategy.

| Genes | mRNAs | lncRNAs | miRNAs | circRNAs | Proteins | PTMs | Metabolites |
|-------|--------|---------|---------|----------|----------|------|-------------|
| TP53  | PRKCI  | HULC    | miR-21  | circ_0001445 | GP73 (18) | AFP-L3 (Fuc) | 1-methyladenosine (34) |
|       | (22–29) | (30)    | (32)    | (46)      |          | (6, 7) |             |
| CTNNB1 | CLEC1B | CYTOR   | miR-203 | circ_0001445 | DCP (5) | A1AT (Fuc) | Xanthine (44) |
| (c.121A > G, c.133T > C) | (30)    | (39)    | (40)    | (46)      |          | (43) |             |
| TERT  | PRC1   | UCA1    | miR-224 | circ_000244 | Hsp90aa (19) | (51) | Fibronectin (Fuc) |
|       | (30)    | (31)    | (45)    | (50)      |          | (51) | Cholylglycine (44) |
| AXIN1 (gene mutation) | YWHAZ | MALAT1  | miR-20a- 3p | circ_104075 | OPN (54) | (55) | Hemopexin (Fuc) |
| (35, 38) | (48)    | (31)    | (49)    | (53)      |          | (55) | D-leucie acid (44) |
| A 32-gene model (52) | ENAH | HMGN4   | miR-30a- 5p | MDK (57) | (61, 62) | (58) | (61, 62) | Paraoxonase-1 (Fuc) |
|       | (48)    | (56)    | (49)    | (67)      |          | (58) | (61, 62) | 3-hydroxy caproic acid (44) |
| p16, p15, RASSF1A (hypermethylation) | SPRY4IT1 | UBE2C2P3 | miR-30a- 3p | GPC3 (8, 9) | (62) | (59) | ACP (Fuc) |
| (58) | (48)    | (31)    | (49)    | (69)      |          | (59) | (62) | Arachidonic lysolecithin (44) |
| APC, GSTP1, RASSF1A, and SFRP1 (hypermethylation) | CAPRIN1 | PTENP1 | miR-122 | ANXA2 (60) | (64) | (65) | Hp (Fuc, Sialic acid) |
|       | (48)    | (31)    | (49)    | (64)      |          | (65) | (64) | Dioleoylphosphatidylcholine (44) |
|       | GHE1T  | (63)    |         | ANXA3 (64) | (65) | (65) | (64) | Acetylcarcinine (66) |
|       |         |         |         | Dkk1 (67) | (70) | (65) | (67) | Butyrylcarcinine (69) |
|       |         |         |         | TRX (70) | ALDOA (P) (71) | (70) | (65) | Hydantoin-5-propionic acid (69) |
|       |         |         |         | PARP1 (72) | ERK1 (P) (73) | (71) | (72) | Choline (74) |
|       |         |         |         |         | (73) | (72) | (73) | Valine (74) |

*Red represents up-regulation in HCC, blue represents down-regulation in HCC.

TP53, Tumor protein 53; CTNNB1, Catenin beta 1; TERT, Telomerase reverse transcriptase; AXIN1, Axin 1; RASSF1A, Ras association domain family 1 isoform A; APC, Adenomatous polyposis coli; GSTP1, Glutathione S-transferase pi-1; SFRP1, Secreted frizzled-related protein 1; YWHAZ, Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta; ENAH, Enabled homolog; HMGN4, High mobility group nucleosomal binding domain 4; CAPRIN1, Cell cycle associated protein 1; HULC, Hepatocellular carcinoma upregulated long noncoding RNA; CYTOR, Cytoskeleton regulator RNA; UCA1, Urothelial carcinoma associated long intergenic noncoding transcript 1; MDK, Midkine; Ku80, Ku80, heat shock protein 90beta; GSTP1, Glutathione S-transferase pi; GPC3, Glypican-3; PARP1, Poly(ADP-ribose) polymerase 1; 7-AAb panel, 7-Amino-actinomycin D; 4E-BP1, 4E-binding protein 1; ALDOA, Aldolase A; ERK1, Extracellular regulated protein kinases 1; ERK2, Extracellular regulated protein kinases 2; LRAP1, Lr-related protein 1; Smad2/3, Mothers against decapentaplegic homolog 2/3; α-HS-glycoprotein; α, Human serum albumin; KLK6, Kallikrein-related peptidase 6; SCOS1, Suppressor of cytokine signaling 1; WDR76, WD40-repeat protein 76; Fuc, Fucosylation; P, Phosphorylation; Ub, Ubiquitination; Ac, Acetylation.
3 PROTEOMICS OF HCC

Many classical proteins, which served as reliable biomarkers for other cancers, have been posing new value in HCC diagnosis. Squamous cell carcinoma antigen (SCCA) was previously reported to be associated with cervical cancer (114). Recent studies also indicated that it had a significant contribution to the early diagnosis of HCC (70). Protein expression of cytokeratin 19 (CK19) in HCC was low, however, it would reflect the malignant progression of hepatoma cells (83). GP73 (18), osteopontin (OPN) (54), midkine (MDK) (57), annexin A2 (ANXA2) (60), annexin A3 (ANXA3) (64), dickkopf-1 (DKK1) (67), thioredoxin (TRX) (70) and polymerase 1 (PARP1) (72) have shown diagnostic value for the early diagnosis of liver cancer. Ring finger protein 6 (RNF6) was upregulated and promoted the tumorigenicity of HCC, which might be useful for the detection of HCC at the initial stage (79). A combination of protein markers was also considered for HCC detection, for example, the joint diagnosis with AFP and fibronectin 1 (76). A novel 7-autoantibody (AAb) panel containing CIAPIN1, EGFR, MAS1, SLC44A3, ASAH1, UBL7 and ZNF428 was identified using HCC-focused array (77). The artificial neural network model was established for this panel and it was also able to detect AFP-negative HCC with AUC values of 0.841-0.948. Further, proteogenomics was used to address the complex biological properties of cancer and it could incorporate proteomics into genomic-level studies to obtain more accurate cancer information (115).

4 POST-TRANSLATIONAL MODIFICATIONS (PTMs) OF HCC

PTMs such as glycosylation, phosphorylation, acetylation and ubiquitination play vital roles in multiple physiological processes and disease progression, including control of the cell cycle progression, changes of chromatin structures and transduction of cellular signals (116). We have summarized potential biomarkers with different PTMs in Figure 1.

Glycosylation of HCC

Tremendous evidence illustrated that glycan structures were altered in cancers (117, 118). Cancer-associated glycosylation aberration provides novel biomarkers by utilizing glycomic/glycoproteomic technologies (119–123). For example, the glycan profile has been assessed to predict the development of HCC in cirrhosis (124). Glycomics is to detect glycans attached to macromolecules such as proteins (7, 119, 121, 125) and glycoproteomics is a high-throughput technique that could reveal glycosylation sites and site-specific glycoforms (126).

Different glycosylation patterns mainly occur in fucosylation, fucan branching, sialylation and terminal N-acetylgalactosamine (127–129). It was reported that increased fucosylated N-glycans played crucial roles in cancer development, such as core-α1,6-fucosylated triantennary glycan (130–132). Fucosylation of α1-acid glycoprotein (AGP) was increased in patients with liver cirrhosis and HCC. Meanwhile, different degrees of fucosylation could further distinguish HCC from liver cirrhosis. Thus, determining the specific changes of AGP glycan structures could be helpful for HCC detection (59). The combination of trifucosylated N-glycan of AGP, AFP and AGP showed superiority in discriminating HCC from liver cirrhosis. Zhu et al. investigated the alterations in fucosylation degree of serum haptoglobin (Hp) in a cohort, which included healthy controls, liver cirrhosis and HCC patients, and also confirmed that the fucosylation abnormalities of Hp were closely related to HCC (62). The mono- and triantennary glycan at Asn184 and Asn241 of Hp had the diagnostic potential for HCC patients (133). In addition, enhanced fucosylation of serum paraoxonase 1 (PON1) (58), α-1-antitrypsin (A1AT) (43), hemopexin (Hpx) (55), complement C3 (C3), ceruloplasmin (CE), histidine-rich glycoprotein (HRG), CD14 (65) and fibrinogen (51) have been reported to be potential glycobiomarkers for early-stage HCC detection.

High-mannose levels were reported to be associated with HCC (134, 135). Previous studies have shown that N-glycosylation changes occurred in the progression of HCC (136). A total of 83 N-glycans was identified in HCC, and among them, 57 had alterations (137). Two glycopeptides of IgA2 might be unique glycan signatures and provided diagnostic clues in HBV-related liver cancer (138). Apolipoprotein J (Apo-J) in HCC had decreased levels of triantennary glycan and the level of glycosylation of Apo-J could differentiate HCC from cirrhosis with an AUC of 0.852 (47). Besides, sialylation played an important role in cell recognition, adhesion and signal transduction. The high content of sialic acid has been observed in HCC (139). Three glycans containing sialic acid have been regarded as candidate markers for the detection of HCC and they could differentiate HCC from CLD with the AUC of 0.89-0.93 (140). The sialylated glycans of serum Hp were also elevated in HCC (61, 141).

Phosphorylation of HCC

Aberrant protein phosphorylation is associated with HCC (142) and more phosphorylation alterations have been elucidated with the development of omics methods. Elevating phosphorylation levels of 4E-binding protein 1 (4E-BP1) on Thr46 could be used to predict the early recurrence and metastasis of HCC (68). The level of Ser36 phosphorylation of aldolase A (ALDOA) was increased and could be used as a potential biomarker for HCC (71). Changes of some phosphorylation sites, such as the remarkable downregulation of pT185 on extracellular regulated protein kinases 2 (ERK2) and pY204 on extracellular regulated protein kinases 1 (ERK1), have contributed to the progression of HCC (73). Phosphorylation of plectin-1 (phospho-Ser-4253) and α-HS-glycoprotein (phospho-Ser 138 and 312) were also found to be potential HCC biomarkers (84). Furthermore, phosphorylation of la-related protein 1 (LARP1)-T449 and mothers against decapentaplegic homolog 2/3 (Smad2/3)-Thr8 could be useful for HCC detection (78, 80).
Ubiquitination of HCC

Ubiquitination modification, mediating protein enzymatic degradation by labeling proteins, plays a critical role in tumorigenesis (143). The change of Lys48-linked ubiquitination in heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) inhibited HNRNPA1-dependent pyruvate kinase isozyme splicing, and subsequently promoted glucose metabolism reprogramming and malignant behavior of cells in HCC (144). Kallikrein-related peptidase 6 (KLK6) and its catalytic products Ubi1-74 could identify cirrhotic patients at risk of developing HCC (86). The ubiquitination levels of several proteins could serve as HCC indicators, such as lupus Ku autoantigen protein p80 (Ku80) (85), suppressor of cytokine signaling 1 (SOCS1) (87) and WD40-repeat protein 76 (WDR76) (88).

Acetylation of HCC

Acetylation modification, as a dynamic and particular component of PTMs, has attracted more attention in recent years. Lysine acetylation is regulated by the interaction between acetylase and deacetylase (145). Increasing evidence has shown that lysine acetylation played a pivotal role in metabolic function and cellular signaling transduction in the occurrence and development of HCC (63, 146). The sites of lysine acetylation in non-histone proteins and histone proteins have been studied in liver tissues (147, 148). Using MS detection, the acetylation at K194, K211 and K242 of AFP provided novel markers and therapeutic targets for HCC (89). Additionally, the acetylation levels of lysine 120 in histone H2B, lysine 18 in histone H3.3 and lysine 77 in histone H4 were found to be increased in HCC (91). Core histone H3 is another highly conserved protein in cell nucleus and its acetylation has indicated diagnostic significance in HCC (90).

5 METABOLOMICS OF HCC

Metabolites with low molecular weight such as < 1.5 kDa can be defined as “metabolome”, and these small molecular metabolites can dynamically change in liver diseases (149). Metabolomics is a
high-throughput method to identify and measure metabolites and offers an opportunity to discover biomarkers (150). Many metabolites were identified including xanthine, uric acid, cholyglycine, D-leucic acid, 3-hydroxy caproic acid, arachidonic acid, lyssolecithin and dioleoylphosphatidylcholine. They could be effective for the discrimination of HCC from HCV (44). Serum acetylcarnitine enabled clinicians to detect HCC from liver cirrhosis (66). In addition, palmitic acid made a distinction between liver cirrhosis and HBV. The 5-methoxytryptamine, malic acid and phenylalanine were used to discriminate HBV and normal controls. The β-glutamate and asparagine were potential liver disease-specific biomarkers to distinguish HCC from liver cirrhosis (74). Serum 1-methyladenosine was identified as a characteristic metabolite for HCC (34). Two metabolites, butyrylcarnitine and hydantoin-5-propionic acid could be combined together to detect HCC (69). A total of 169 genes and 28 metabolites was reported to be different including xanthine, uric acid, cholyglycine, D-leucic acid, 3-hydroxy caproic acid, arachidonic acid, lyssolecithin and dioleoylphosphatidylcholine. They could be effective for the discrimination of HCC from HCV (44). Serum acetylcarnitine enabled clinicians to detect HCC from liver cirrhosis (66). In addition, palmitic acid made a distinction between liver cirrhosis and HBV. The 5-methoxytryptamine, malic acid and phenylalanine were used to discriminate HBV and normal controls. The β-glutamate and asparagine were potential liver disease-specific biomarkers to distinguish HCC from liver cirrhosis (74). Serum 1-methyladenosine was identified as a characteristic metabolite for HCC (34). Two metabolites, butyrylcarnitine and hydantoin-5-propionic acid could be combined together to detect HCC (69). A total of 169 genes and 28 metabolites was reported to be associated with HCC (81). The product of stearoyl CoA desaturase, monounsaturated palmitic acid, increased the invasiveness of HCC, enhanced the migration ability of HCC cells in vitro and might be helpful for HCC diagnosis.

DISCUSSION

Oomics technologies and analytical software have been improved. For glycosylation, pGlyco (151), StrucGP (152), GPQuest and GlycoPAT (153) helped to obtain detailed and accurate data. Multi-omics proposed more biomarkers and the specificity and sensitivity of these biomarkers still need to be comprehensively evaluated. Previous studies showed that the profile of DNA methylation had high tissue specificity and helped to determine the tissue origin of cfDNAs (154–157). The combination of different oomics biomarkers and the application of computational models can increase diagnostic accuracy. For example, monitoring the change of HCC-specific CpG island methylator phenotype in company with AFP was proved to have better diagnostic performance (158). Measuring both Mac-2 binding protein glycosylation isomer (M2BPGi) and AFP improved the detection sensitivity (159). Metabolites such as phenylalanyl-tryptophan and glycocholate could be added to the traditional HCC diagnostic process to achieve early detection (82).

Different types of biomarkers and detection methods have their advantages and applicable fields. The changes of some proteins and cfDNAs can be detected in the early stages of cancer and they may have high sensitivity for detecting high-risk patients. Considering the affinity of lectin and glycan-specific antibodies to their corresponding glycosylated structures may be low, so its detection usually needs more complex methods (160, 161). Milliliters of plasma were often used for cfDNA extraction (162); micrograms of proteins or microliters of serum seem to be enough for PTM determination (163); for metabolites, microliters of serum were often considered (164). Thus, different methods need to be considered and improved to promote clinic application of multi-omics biomarkers.

CONCLUSION

The combination of multi-omics, including genomics, transcriptomics, proteomics, glycomics, glycoproteomics and metabolomics would provide more sensitive and accurate detection for HCC, especially in the early stage. Multi-omics approaches also enable the researchers to gain deeper insight into the molecular mechanism of HCC development. With optimized technologies and clinical validation, multi-omics biomarkers would become practical in clinic for HCC diagnosis.

AUTHOR CONTRIBUTIONS

FC and SZ collected information and wrote the manuscript. JW made the table and drew the figure. YW made modifications to the manuscript. QG and SZ formulated the writing frame and made important modifications to the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

The work was supported by the Science and Technology Commission of Shanghai Municipality (20JC1418900) and Shanghai Pujiang Program (2020PJ012).

REFERENCES

1. Villanueva A. Hepatocellular Carcinoma. N Engl J Med (2019) 380 (15):1450–62. doi: 10.1056/NEJMra1713263
2. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nat Rev Gastroenterol Hepatol (2019) 16(10):589–604. doi: 10.1038/s41575-019-0186-y
3. Rinella ME. Nonalcoholic Fatty Liver Disease: A Systematic Review. JAMA (2015) 313(22):2263–73. doi: 10.1001/jama.2015.5370
4. Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, Sereste T, et al. Alcohol Intake Increases the Risk of HCC in Hepatitis C Virus-Related Compensated Cirrhosis: A Prospective Study. J Hepatol (2016) 65(3):543–51. doi: 10.1016/j.jhep.2016.04.031
5. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-Fetoprotein, Des-Gamma Carboxyprothrombin, and Lectin-Bound Alpha-Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterol (2009) 137(1):110–8. doi: 10.1053/j.gastro.2009.04.005
6. Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. Hepatol (2019) 69(5):1983–94. doi: 10.1002/hep.30233
7. Nakagawa T, Miyoshi E, Yukushijin T, Hiramatsu N, Ighara T, Hayashi N, et al. Glycomic Analysis of Alpha-Fetoprotein L3 in Hepatoma Cell Lines
Chen et al. HCC Biomarkers Using Multi-Omics

18. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. MS-Based Biomarker Screening for Hepatocellular Carcinoma Diagnosis and Treatment. Med Res Rev (2018) 38 (2):741–67. doi: 10.1002.med.21455

19. Zhou J, Shi YH, Fan J. Circulating Cell-Free Nucleic Acids: Promising Biomarkers for Hepatocellular Carcinoma. *Gastroenterology* (2003) 125(1):89–97. doi: 10.1016/S0016-5085(03)00689-9

20. Peng W, Gutierrez Reyes CD, Gautam S, Yu A, Cho BG, Goli M, et al. Genomic Profiling of Combined Hepatocellular-Cholangiocarcinoma Reveals Similar Genetics to Hepatocellular Carcinoma. *J Pathol* (2019) 248 (2):164–78. doi: 10.1002/path.5243

21. Li VD, Li KH, Li JT. TP53 Mutations as Potential Prognostic Markers for Specific Cancers: Analysis of Data From The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. *J Cancer Res Clin Oncol* (2019) 145(3):625–36. doi: 10.1007/s00432-018-2817-z

22. Kaur H, Dhall A, Kumar R, Raghava GPS. Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale Transcriptomics Data. *Front Genet* (2019) 10:1306. doi: 10.3389/fgen.2019.01306

23. Huang J, Zheng R, Yao X, Liu C, Lin J, Zheng S, et al. A Circulating Long Noncoding RNA Panel Serves as a Diagnostic Marker for Hepatocellular Carcinoma. *Dis Markers* (2020) 2020:517958. doi: 10.1155/2020/517958

24. Tomimura Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a Novel Biomarker for Hepatocellular Carcinoma. *Int J Cancer* (2012) 131(1):31–7. doi: 10.1002/ijc.29227

25. Villanueva A, Hoshida Y. Depicting the Role of TP53 in Hepatocellular Carcinoma Progression. *J Hepatol* (2011) 55(3):724–5. doi: 10.1016/j.jhep.2011.03.018

26. Ieda S, Lim JS, Kuruzzo R. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. *Mol Cancer Ther* (2018) 17(5):1114–22. doi: 10.1158/1535-7163.MCT-17-0604

27. Paget V, Sichel F, Gauthier A, Chevrel M. Aflatoxin B1-Induced TP53 Mutational Pattern in Normal Human Cells Using the FASAY (Functional Analysis of Separated Alleles in Yeast). *Mutat Res* (2008) 656(1-2):55–61. doi: 10.1016/j.margen.2008.07.009

28. Josep NM, Tsokos CG, Uematsu SE, Shain AH, Kelley RK, Onodera C, et al. Genomic Profiling of Combined Hepatocellular-Cholangiocarcinoma. *Cancer Res* (2019) 79(9):2941–52. doi: 10.1158/0008-5472.CAN-18-1257

29. Bowers J, Hughes E, Skill N, Maluccio M, Raftery D. Detection of Hepatocellular Carcinoma in Hepatitis C Patients: Biomarker Discovery and Hepatocellular Carcinoma Patients. *J Proteome Res* (2008) 7(6):2222–33. doi: 10.1021/pr070084q

30. Caprullo M, Wierusz RK, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: A Novel Serum and Histochemical Marker for Hepatocellular Carcinoma. *Gastroenterology* (2003) 125(1):89–97. doi: 10.1016/S0016-5085(03)00689-9
Benicky J, Sanda M, Pompach P, Wu J, Goldman R. Quantification of circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. J Proteome Res (2015) 14(11):4876–84. doi: 10.1021/acs.jproteome.5b00718

Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA. J Cell Physiol (2019) 234(4):4851–63. doi: 10.1002/jcp.27283

Chen et al. HCC Biomarkers Using Multi-Omics

Chen et al. HCC Biomarkers Using Multi-Omics

Chen et al. HCC Biomarkers Using Multi-Omics
Chen et al. HCC Biomarkers Using Multi-Omics

97. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated With Progression of Hepatocellular Carcinoma and Patient Outcomes. *Gastroenterol* (2013) 144(5):1066–75.1. doi: 10.1053/j.gastro.2013.01.054

98. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebourssou S, et al. Exome Sequencing of Hepatocellular Carcinomas Identifies New Mutational Signatures and Potential Therapeutic Targets. *Nat Genet* (2015) 47(5):503–11. doi: 10.1038/ng.3252

99. Mann J, Reeves HL, Feldstein AE. Liquid Biopsy for Liver Diseases. *Gut* (2018) 67(12):2204–12. doi: 10.1136/gutjnl-2017-315846

100. Branco MR, Ficz G, Reik W. Uncovering the Role of 5-Hydroxymethylcytosine in the Epigenome. *Nat Rev Genet* (2011) 13(1):7–13. doi: 10.1038/nrg3080

101. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asahuka H. P16(INK4) is Inactivated by Extensive Cpg Methylation in Human Hepatocellular Carcinoma. *Gastroenterol* (1999) 116(2):394–400. doi: 10.1016/S0016-5085(99)70137-X

102. Rencacci S, Bianchi P, Bruni B, Laghi L, Destratto A, Di Gioia S, et al. Methylation Framework of Cell Cycle Gene Inhibitors in Cirrhosis and Associated Hepatocellular Carcinoma. *Hepatol* (2002) 36(2):427–32. doi: 10.1053/jhep.2002.34852

103. Zhong S, Tang MW, Yeo W, Liu CL, Li DJ, Johnson PJ. Silencing of GSTP1 Gene by Cpg Island DNA Hypermethylation in HBV-Associated Hepatocellular Carcinomas. *Clin Cancer Res* (2002) 8(4):1087–92.

104. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative Analysis of Multiple Methylated Genes in Plasma for the Diagnosis and Prognosis of Hepatocellular Carcinoma. *Exp Mol Pathol* (2011) 91(3):702–7. doi: 10.1016/j.yexmp.2011.08.004

105. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G, et al. aberrant Cpg Island Hypermethylation in Dysplastic Nodules and Early HCC of Hepatitis B Virus-Related Human Multistep Hepatocarcinogenesis. *J Hepatol* (2011) 54(3):939–47. doi: 10.1016/j.jhep.2010.08.021

106. Zhou Y, Deng X, Zang N, Li H, Li G, Li C, et al. Transcriptional and Proteomic Investigation of HSP90α as a Potential Biomarker for HCC. *Med Sci Monit* (2015) 21:4039–49. doi: 10.12659/msm.896712

107. Chen X, Tang FR, Arfuso F, Cai WQ, Ma Z, Yang J, et al. The Emerging Role of Long Non-Coding RNAs in the Metastasis of Hepatocellular Carcinoma. *Exp Cell Res* (2021) 325:101486. doi: 10.1016/j.yexcr.2021.101486

108. Lin YH, Wu MH, Yeh CT, Lin KH. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication. Int J Mol Sci (2018) 19(12):3742. doi: 10.3390/ijms19123742

109. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-Coding RNAs in GI Cancers: From Cancer Hallmarks to Clinical Utility. *Gut* (2020) 69(4):748–63. doi: 10.1136/gutjnl-2019-318279

110. El Khodiry A, Afify M, El Tayebi HM. Behind the Curtain of non-Coding RNAs: Long non-coding RNAs Regulating Hepatocarcinogenesis. *World J Gastroenterol* (2018) 24(3):549–72. doi: 10.3748/wjg.v24.i3.549

111. Zhang H, Chen X, Zhang J, Wang X, Chen H, Liu L, et al. Long Noncoding RNAs in HBV-Related Hepatocellular Carcinoma (Review). *Int J Oncol* (2020) 56(1):18–32. doi: 10.3892/ijoi.2019.4909

112. Lim LJ, Wong SY, Huang F, Lim S, Chong SS, Ooi LL, et al. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma. *Cancer Res* (2019) 79(20):5131–9. doi: 10.1158/0008-5472.CAN-19-0255

113. Chen B, Butte AJ. Leveraging Big Data to Transform Target Selection and Drug Discovery. *Clin Pharmacol Ther* (2016) 99(3):285–97. doi: 10.1002/cpt.318

114. Lee WK, Chong GO, Jeong SY, Lee HJ, Park SH, Ryu JM, et al. Prognosis-Predicting Model Based on [18F]fluorodeoxyglucose PET Metabolic Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy: Multi-Center Retrospective Study. *J Clin Med* (2020) 9(2):427. doi: 10.3390/jcm9020427

115. Zhang B, Whiteaker JR, Hoofnagle AN, Baird GS, Rodland KD, Paulovich AG. Clinical Potential of Mass Spectrometry-Based Proteogenomics. *Nat Rev Clin Oncol* (2016) 13(4):256–68. doi: 10.1038/s41571-018-0135-7

116. Chen L, Liu S, Tao Y. Regulating Tumor Suppressor Genes: Post-Translational Modifications. *Signal Transduct Target Ther* (2020) 5(1):90. doi: 10.1038/s41392-020-0196-9

117. Zhang S, Cao X, Gao Q, Liu Y. Protein Glycosylation in Viral Hepatitis-Related HCC: Characterization of Heterogeneity, Biological Roles, and Clinical Implications. *Cancer Lett* (2017) 406:64–70. doi: 10.1016/j.canlet.2017.07.026
157. Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, et al. Plasma DNA Tissue Mapping by Genome-Wide Methylation Sequencing for Noninvasive Prenatal, Cancer, and Transplantation Assessments. Proc Natl Acad Sci USA (2015) 112(40):ES503–12. doi: 10.1073/pnas.1508736112

158. Cheng J, Wei D, Ji Y, Chen L, Yang L, Li G, et al. Integrative Analysis of DNA Methylation and Gene Expression Reveals Hepatocellular Carcinoma-Specific Diagnostic Biomarkers. Genome Med (2018) 10(1):42. doi: 10.1186/s13073-018-0548-z

159. Inoue T, Tanaka Y. Novel Biomarkers for the Management of Chronic Hepatitis B. Clin Mol Hepatol (2020) 26(3):261–79. doi: 10.3350/cmh.2020.0032

160. Zhang S, Li W, Lu H, Liu Y. Quantification of N-Glycosylation Site Occupancy Status Based on Labeling/Label-Free Strategies With LC-Ms/MS. Talanta (2017) 170:509–13. doi: 10.1016/j.talanta.2017.04.053

161. Du X, Lu J, Yang L, Bao H, Zhang L, Yan G, et al. Rapid and Easy Enrichment Strategy for Naturally Acetylated N Termini Based on LysN Digestion and Amine-Reactive Resin Capture. Anal Chem (2020) 92(12):8315–22. doi: 10.1021/acs.analchem.0c00695

162. Del Giacco L, Cattaneo C. Introduction to Genomics. Methods Mol Biol (2012) 823:79–88. doi: 10.1007/978-1-60327-216-2_6

163. He Y, Mohamedali A, Huang C, Baker MS, Nice EC. Oncoproteomics: Current Status and Future Opportunities. Clin Chim Acta (2019) 495:611–24. doi: 10.1016/j.cca.2019.06.006

164. Wang S, Blair IA, Mesaros C. Analytical Methods for Mass Spectrometry-Based Metabolomics Studies. Adv Exp Med Biol (2019) 1140:635–47. doi: 10.1007/978-3-030-15990-4_38

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Wang, Wu, Gao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.